Pfizer enlarges market defense position through high-volume Celebrex

Pfizer Korea has targeted generics of Celebrex(celecoxib), a blockbuster treatment, by volume diversification. Its high-volume 400mg product has been newly approved, and the 100mg product is also planned to be launched.

The Ministry of Food and Drug Safety(MFDS) approved commercialization of Celebrex 400mg on the 22^nd. Its indications are ankylosing spondylitis relief, adult acute pain relief ...